Simris Alg AB (publ)
The answer first
Does Simris Alg beat the market?
No, Simris Alg has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 10% of Nordic stocks
- Quality16
- Value1
- Trend64
No. 162 of 195 in healthcare
Max for seven days
Follow Simris Alg with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Simris Alg
Your first answer is free, no account needed.
Do you own Simris Alg, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Simris Alg and a few more. Free, no card.
Super Stock+45.9%In short
- Simris Alg has fallen 18.0% over the past year, including dividends.
- Overall, Simris Alg ranks better than 10% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 93.6%. The price is 99.0% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 10% of Nordic stocks.
No. 162 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 175 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.01
- Return on equityProfit divided by equity−492.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 191 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity23.0
- P/SPrice divided by sales104.4
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 57 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−3.7%
- 6 months+11.0%
- 9 months+21.5%
- 12 months−18.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Simris Alg
Simris Alg AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.


See the full analysis of Simris Alg.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card